zealand pharma obesity

Roche-Zealand deal is latest to boost obesity space

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

CNBC on MSN · 2d

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Seeking Alpha on MSN · 2d

Roche, Zealand Pharma enter $5.3B license deal for obesity treatment

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the terms of deal,

Fierce Biotech2d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

STAT2d

Roche partners with Zealand Pharma to push forward obesity drug

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Roche-Zealand deal is latest to boost obesity space

Trending now